Sekhmet Pharmaventures targets to hit ₹2,000 crore revenue in 3 years

Sekhmet Pharmaventures has announced a strategic expansion plan aimed at significantly growing its business scale. The company has set a target to achieve a revenue of ₹2,000 crore within the next three years. To support this growth, the firm plans to invest between ₹125 crore and ₹150 crore in capital expenditure. A major portion of this funding will be sourced from the company's own internal accruals, indicating a disciplined approach to financing the expansion.

This move is significant for investors as it signals Sekhmet's intent to scale up operations and increase its market footprint. By focusing on internal funds rather than external debt, the company aims to strengthen its balance sheet while pursuing aggressive growth targets. The expansion is expected to enhance the company's production capabilities and revenue streams in the coming years.

Investors should monitor the execution of this capex plan and the resulting impact on Sekhmet's operational efficiency. Key factors to watch include the timely completion of the new reactor capacity and the company's ability to maintain profitability while scaling up. The realization of the ₹2,000 crore revenue target will depend on successful market penetration and operational execution.